Philadelphia, PA, October 8, 2003 - MDdatacor, inc. announced today at Barnett International's 8th Annual Strategies to Maximize Patient Recruitment Conference that it has accumulated longitudinal medical data for over two million individual cardiology patients. MDdatacor receives medical information from more than 65 cardiology practices representing approximately 1,200 cardiologists nationwide. The database is the largest available set of de-identified, patient-level cardiology data. MDdatacor uses this database to help physicians deliver superior care to their patients. MDdatacor is beginning to help pharmaceutical and medical device companies accelerate enrollment for clinical trials and uncover unmet demand for their products.

"A year ago we were at 500,000 patients and in six months we doubled to one million patients. We've now reached two million patients and we are still growing fast," commented Blake Whitney, MDdatacor chairman, president and chief executive officer. "Our size and growth allows us to execute large scale projects for our pharmaceutical and medical device customers. MDdatacor has become a valuable asset for significantly reducing the time and cost in clinical trials. Using our solutions, Industry can now help the cardiologists in our network treat hundreds of thousands of at-risk patients. This is a win - win - win strategy."

According to the Parexel's Pharmaceutical R&D Statistical Sourcebook, over 78% of trials are delayed (56% by over one month), with over 50% of these delays resulting from an inability to recruit candidates. MDdatacor identifies research sites with the highest concentrations of patients. MDdatacor also provides a list of eligible candidates for a trial to each site chosen by the pharmaceutical sponsor, improving site selection and accelerating patient enrollment.

MDdatacor also identifies cardiology patients medically indicated for a particular therapy or device, but that have not yet received it. A recent New England Journal of Medicine and RAND Corporation study suggests that, in the U.S., patients are treated to clinical guidelines only 55% of the time. "The success of evidence-based medicine is predicated on the ongoing development of new software tools to refine how the correct drugs ultimately reach the most appropriate patients," says Michael Greeley, managing general partner at IDG Ventures in Boston, MA and a contributing editor of Bio-IT World. "When MDdatacor takes unstructured, patient-level medical data directly from a cardiology practice and turns it into a searchable database, they are overcoming the technical limitations of our healthcare IT infrastructure and lack of standardization."

"MDdatacor can impact a new drug or therapy throughout the lifecycle of the product," added Mr. Whitney. "From clinical development through to commercialization, MDdatacor can find and deliver the patients sought by pharmaceutical and medical device companies."